Stockscreener 앱 받기
157.38
0.46%
0.72
시간 외 거래:
157.38
전일 마감가:
$156.66
열려 있는:
$156.67
하루 거래량:
883.80K
Relative Volume:
0.56
시가총액:
$21.28B
수익:
$1.53B
순이익/손실:
$-214.69M
주가수익비율:
-89.42
EPS:
-1.76
순현금흐름:
$-43.68M
1주 성능:
+2.87%
1개월 성능:
+17.56%
6개월 성능:
+26.52%
1년 성능:
+62.28%
1일 변동 폭
$155.56
$159.15
1주일 범위
$146.34
$159.15
52주 변동 폭
$92.14
$183.00
Natera Inc Stock (NTRA) Company Profile
명칭
Natera Inc
전화
650-249-9090
주소
13011 MCCALLEN PASS, AUSTIN, CA
NTRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
157.38 | 21.28B | 1.53B | -214.69M | -43.68M | -1.76 |
|
TMO
Thermo Fisher Scientific Inc
|
422.27 | 159.05B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.40 | 140.21B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
475.07 | 34.90B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
108.37 | 30.47B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
152.30 | 26.47B | 15.41B | 1.37B | 2.11B | 7.50 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-08 | 재개 | Craig Hallum | Buy |
| 2024-02-20 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | 재확인 | BTIG Research | Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-11-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | 개시 | Bernstein | Mkt Perform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-05 | 개시 | UBS | Buy |
| 2023-01-18 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-04-25 | 개시 | Stephens | Overweight |
| 2022-03-08 | 개시 | Goldman | Buy |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-05-25 | 개시 | Wells Fargo | Overweight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-08 | 개시 | BTIG Research | Buy |
| 2020-09-28 | 개시 | Morgan Stanley | Overweight |
| 2020-09-17 | 개시 | SVB Leerink | Outperform |
| 2020-06-10 | 재개 | Piper Sandler | Overweight |
| 2020-05-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-10-05 | 개시 | JP Morgan | Neutral |
| 2018-07-05 | 재확인 | Piper Jaffray | Overweight |
| 2017-08-07 | 재확인 | Morgan Stanley | Overweight |
| 2016-11-10 | 재확인 | The Benchmark Company | Buy |
| 2016-05-23 | 재확인 | The Benchmark Company | Buy |
| 2016-05-11 | 재확인 | The Benchmark Company | Buy |
| 2016-04-19 | 개시 | The Benchmark Company | Buy |
| 2015-09-28 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2015-08-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | 개시 | Robert W. Baird | Outperform |
| 2015-07-27 | 개시 | Morgan Stanley | Equal-Weight |
| 2015-07-27 | 개시 | Piper Jaffray | Overweight |
| 2015-07-27 | 개시 | Wedbush | Neutral |
모두보기
Natera Inc 주식(NTRA)의 최신 뉴스
Natera (NTRA) Highlights Promising Study Results for Sarcoma Detection | NTRA Stock News - GuruFocus
Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera | NTRA Stock News - GuruFocus
Breakthrough: Largest-Ever Sarcoma Study Validates Natera's Cancer Detection Test with 93% Accuracy - Stock Titan
Learn to Evaluate (NTRA) using the Charts - news.stocktradersdaily.com
CLASS ACTION: Kessler Topaz Meltzer & Check, LLP Reminds Natera, Inc. Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors with Losses over $250,000 to Contact the Firm - Newsfile
Notice to Shareholders of Natera, Inc. (NTRA) Regarding Dismissal of Putative Investor Class Action - TradingView
Natera to Report its First Quarter Results on May 8, 2025 - BioSpace
Natera’s chief legal officer sells $303,299 in stock By Investing.com - Investing.com South Africa
Natera executive chairman sells shares for $261,449 By Investing.com - Investing.com Canada
Natera president Solomon Moshkevich sells $335,714 in stock By Investing.com - Investing.com South Africa
Natera executive chairman sells shares for $261,449 - Investing.com Australia
Natera co-founder Sheena Jonathan sells $66,808 in stock By Investing.com - Investing.com Canada
Natera co-founder Sheena Jonathan sells $66,808 in stock - Investing.com Australia
Natera’s chief legal officer sells $303,299 in stock - Investing.com
Natera (NasdaqGS:NTRA) Unveils DEFINE-HT Trial Insights in Heart Transplantation Study - Yahoo Finance
Minimal Residual Disease Testing Market Outlook 2024-2031 | Growth Led by Myriad, Natera & Guardant - openPR.com
Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today - Benzinga
Natera, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
Natera, Inc. (NTRA): One of the Best Aggressive Growth Stocks to Buy Now - Insider Monkey
Natera launches Signatera Genome assay nationwide By Investing.com - Investing.com India
Natera Inc (NTRA) Shares Up 3.01% on Apr 24 - GuruFocus
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test - BioSpace
Natera launches Signatera Genome assay nationwide - Investing.com Australia
Natera, Inc. to Present Data from 8 Studies at 2025 AACR Annual Meeting - marketscreener.com
Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting - BioSpace
Natera CFO Michael Burkes Brophy sells $88,784 in stock By Investing.com - Investing.com Nigeria
Natera CFO Michael Burkes Brophy sells $88,784 in stock - Investing.com
Natera Executives and Directors Conduct Share Transactions - TradingView
Natera To Present Data from 8 Studies at 2025 AACR Annual Meetin - GuruFocus
Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting | NTRA Stock News - GuruFocus
Long Term Trading Analysis for (NTRA) - news.stocktradersdaily.com
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today - Benzinga
The Blood Test Revolution Driving These Three Stocks - Investor's Business Daily
Lobbying Update: $140,000 of NATERA INC lobbying was just disclosed - Nasdaq
When will cancer return? Personalized Signatera blood test can find early signs of disease - Austin American-Statesman
Natera (NasdaqGS:NTRA) Climbs 11% in One Week - simplywall.st
Barclays Adjusts Natera (NTRA) Price Target Amid Industry Challe - GuruFocus
Assessing Natera: Insights From 10 Financial Analysts - Benzinga
When Will Natera, Inc. (NASDAQ:NTRA) Turn A Profit? - Yahoo Finance
Natera Inc (NTRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.59%
자본화:
|
볼륨(24시간):